View Video Duration: 1 hour 30 minutes
New therapies – particularly probiotic products and microbiota transplants – are challenging the regulatory approaches of the FDA and FTC. Probiotic food and dietary supplement products are proliferating in the marketplace, making a diverse array of health claims. At the same time, microbiota transplants – fecal, vaginal, skin, mouth and nasal cavity – are being used, or proposed, to treat serious medical conditions. Prof. Hoffmann discussed the issues presented by these therapies and their marketing and advertising, as well as possible ways to address them.
Co-sponsored by the University of Minnesota’s BioTechnology Institute and the Microbiota Therapeutics Program